Beyond Access: The hidden factors behind active ageing in communities
Peer-Reviewed Publication
Updates every hour. Last Updated: 12-Oct-2025 19:11 ET (12-Oct-2025 23:11 GMT/UTC)
New research from the University of Bath shows it's not just about how many opportunities older adults have to be active — it’s about how good those opportunities are.
The use of this test in clinical practice would allow for the avoidance of side effects and the implementation of more effective treatment. "We've found a way to practice precision medicine with standard chemotherapy," says Geoff Macintyre, a researcher at the Spanish National Cancer Research Centre (CNIO). The research has been published in the journal Nature Genetics. The test will now be validated in a hospital setting, thanks to a new project funded by the Spanish Ministry for Digital Transformation and Public Service.
Cancer Research UK-funded scientists at the University of Cambridge create a test to predict resistance to chemotherapy. The test uses changes to cancer DNA at diagnosis to predict which patients will be resistant to three common types of chemotherapy. New method could benefit thousands of patients every year by helping them avoid treatments that are less likely to benefit them.
A team led by Prof. Zhenke Zhu from Ningbo University analyzed 261 soil samples across China to systematically compare the impacts of different legume crop rotations on soil properties and microbial communities, revealing the unique advantages of faba bean (Vicia faba) rotation in enhancing soil multifunctionality and its microbial-driven mechanisms. The relevant paper has been published in Frontiers of Agricultural Science and Engineering (DOI: 10.15302/J-FASE-2025604).
In a paper published in MedComm – Future Medicine, a Chinese research team presents ImmunoCheckDB, a comprehensive web platform integrating meta-analysis and multiomic data to discover cancer immunotherapy biomarkers. The platform curates 173 studies on immune checkpoint inhibitor (ICI) therapies, covering survival outcomes for 93,234 individuals across 18 cancer types and 30 ICI regimens, enabling pan-cancer exploration of molecular markers for ICI efficacy.